A recent report from the European Commission highlights the increasing importance of payer considerations in demonstrating product value through clinical development programmes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Hughes, B. Payers growing influence on R&D decision making. Nat Rev Drug Discov 7, 876–878 (2008). https://doi.org/10.1038/nrd2749
Issue Date:
DOI: https://doi.org/10.1038/nrd2749
This article is cited by
-
News in brief
Nature Reviews Drug Discovery (2010)
-
2008 in reflection
Nature Reviews Drug Discovery (2009)